Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPGUCF)

Drug Name
Dopamine Drug Info
Synonyms
Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Approved [1] , [2]
Hypotension BA20-BA21 Phase 1 [1] , [3]
Therapeutic Class
Cardiotonic Agents
Cross-matching ID
PubChem CID
681
ChEBI ID
CHEBI:18243
CAS Number
CAS 51-61-6
TTD Drug ID
DMPGUCF
VARIDT Drug ID
DR00283
INTEDE Drug ID
DR0532
ACDINA Drug ID
D00212

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [4] , [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID Highest Status REF
Synaptic vesicle glycoprotein 2C (SLC22B3) DT7A9GF SV2C_HUMAN Approved [6]
Vesicular amine transporter 2 (SLC18A2) DTT7VPB VMAT2_HUMAN Approved [7]
Vesicular amine transporter 1 (SLC18A1) DTM953D VMAT1_HUMAN Approved [7]
Sodium-dependent dopamine transporter (SLC6A3) DT3BA8L SC6A3_HUMAN Approved [8]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Approved [9]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Approved [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Approved [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Approved [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Approved [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Approved [12]
Catechol O-methyltransferase (COMT) DEV3T4A COMT_HUMAN Approved [13]
Sulfotransferase 1B1 (SULT1B1) DED5UR3 ST1B1_HUMAN Approved [14]
Monoamine oxidase type B (MAO-B) DET2NXO AOFB_HUMAN Approved [15]
Dopamine dehydroxylase (dadH) DEL0D64 DADH_EGGLN Approved [16]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dopamine D2 receptor (D2R) DTT DRD2 5.345 5.634 5.789 5.901
Vesicular amine transporter 2 (SLC18A2) DTP VMAT2 0.766 3 2.263 3.35
Organic cation transporter 1 (SLC22A1) DTP OCT1 10.261 4.162 4.07 3.797
Vesicular amine transporter 1 (SLC18A1) DTP VMAT1 3.828 5.166 2.807 3.597
Organic cation transporter 2 (SLC22A2) DTP OCT2 3.766 3.548 7.303 3.548
Sodium-dependent dopamine transporter (SLC6A3) DTP DAT1 4 2.609 5.233 3.7
Catechol O-methyltransferase (COMT) DME COMT 7.953 6.258 6.784 6.575
Monoamine oxidase type B (MAO-B) DME MAOB 9.367 6.907 8.237 8.409
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 10.036 5.779 6.508 6.481
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.867 5.142 5.52 7.08
Sulfotransferase 1B1 (SULT1B1) DME SULT1B1 7.05 7.571 6.446 7.906
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 3.307 5.005 3.921 5.327
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 11.76 5.931 6.164 9.423
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Vesicular amine transporter 2 (SLC18A2) DTP VMAT2 2.69E-02 -4.44E-02 -1.12E-01
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 8.54E-01 1.24E-02 7.20E-02
Vesicular amine transporter 1 (SLC18A1) DTP VMAT1 2.65E-02 -4.30E-02 -2.34E-01
Organic cation transporter 2 (SLC22A2) DTP SLC22A2 8.22E-01 -1.05E-02 -3.83E-02
Synaptic vesicle glycoprotein 2C (SLC22B3) DTP SV2C 9.35E-01 -5.10E-02 -6.99E-02
Sodium-dependent dopamine transporter (SLC6A3) DTP DAT1 2.11E-01 1.59E-02 5.57E-02
Catechol O-methyltransferase (COMT) DME COMT 5.00E-03 9.63E-02 4.48E-01
Monoamine oxidase type B (MAO-B) DME MAOB 2.65E-02 1.12E-02 6.68E-02
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Sulfotransferase 1B1 (SULT1B1) DME SULT1B1 1.61E-01 2.35E-03 1.15E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 940).
2 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
5 Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet. 2007Sep 5;144B(6):809-15.
6 Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
7 SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
8 Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
9 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
10 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
11 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
12 Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8.
13 Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60.
14 Molecular cloning, expression, and functional characterization of novel mouse sulfotransferases. Biochem Biophys Res Commun. 1998 Jun 29;247(3):681-6.
15 Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.
16 Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.